We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

133 hedge funds and large institutions have $555M invested in CTI BioPharma Corp. (DE) Common Stock in 2022 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 44 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 12

12% more funds holding

Funds holding: 119 → 133 (+14)

9% more capital invested

Capital invested by funds: $510M → $555M (+$44.6M)

9% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 44

19% less call options, than puts

Call options by funds: $5.83M | Put options by funds: $7.21M

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
133
Holders Change
+14
Holders Change %
+11.76%
% of All Funds
2.29%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.07%
New
27
Increased
48
Reduced
44
Closed
12
Calls
$5.83M
Puts
$7.21M
Net Calls
-$1.39M
Net Calls Change
-$4.8M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$24.3M
2
SCM
Stonepine Capital Management
Oregon
+$12.4M
3
DCM
Driehaus Capital Management
Illinois
+$10.2M
4
Millennium Management
Millennium Management
New York
+$9.88M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$8.02M

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$27.2M
2
FFM
Fairmount Funds Management
Pennsylvania
-$13.4M
3
Two Sigma Investments
Two Sigma Investments
New York
-$7.5M
4
LPC
Lion Point Capital
New York
-$6.86M
5
Invesco
Invesco
Georgia
-$5.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$5.5M -$355K -57,000 -6%
Northern Trust
27
Northern Trust
Illinois
$4.68M +$306K +49,100 +6%
PA
28
Perceptive Advisors
New York
$4.28M +$4.58M +735,165 New
Morgan Stanley
29
Morgan Stanley
New York
$4.22M -$904K -144,991 -17%
Bank of America
30
Bank of America
North Carolina
$4.16M +$2.85M +457,780 +178%
Ensign Peak Advisors
31
Ensign Peak Advisors
Utah
$4.11M +$3.47M +557,186 +374%
Barclays
32
Barclays
United Kingdom
$3.95M +$4.2M +673,949 +14,450%
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$3.75M +$2.56M +411,568 +177%
IM
34
Islet Management
New York
$3.64M -$2.34M -375,000 -38%
DMKJ
35
David M. Knott Jr
$3.3M – – –
Invesco
36
Invesco
Georgia
$3.13M -$5.25M -843,023 -61%
Citadel Advisors
37
Citadel Advisors
Florida
$2.86M -$2.05M -328,777 -40%
EI
38
EAM Investors
California
$2.74M -$2.31M -371,173 -44%
ACM
39
Altium Capital Management
New York
$2.48M +$2.66M +427,000 New
Walleye Capital
40
Walleye Capital
New York
$2.31M +$2.47M +396,972 New
Jane Street
41
Jane Street
New York
$2.23M +$1.22M +195,283 +104%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$2.16M -$769K -123,342 -25%
Russell Investments Group
43
Russell Investments Group
United Kingdom
$2.08M +$2.23M +357,303 New
BNP Paribas Financial Markets
44
BNP Paribas Financial Markets
France
$1.92M +$1.93M +309,640 +1,535%
TCM
45
Tang Capital Management
California
$1.75M +$1.87M +300,000 New
JGC
46
J. Goldman & Co
New York
$1.54M -$643K -103,165 -28%
CSS
47
Cubist Systematic Strategies
Connecticut
$1.54M +$1.25M +200,133 +314%
Charles Schwab
48
Charles Schwab
California
$1.5M +$104K +16,684 +7%
Calamos Advisors
49
Calamos Advisors
Illinois
$1.36M +$1.45M +233,452 New
Two Sigma Investments
50
Two Sigma Investments
New York
$1.14M -$7.5M -1,203,623 -86%
1
2
3 4 5

CTIC Hedge Fund Activity: Q3 2022 in Review

133 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2022, worth a combined $555M — up 8.7% from $510M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CTIC positions and 12 closed out — a net gain of 15 holders — while 48 added to existing stakes and 44 trimmed.

The largest buyer was State Street, adding an estimated $24.3M. The largest seller was NEA Management Company, cutting an estimated $27.2M.

  • 133 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2022, up from 119 in Q2 2022.
  • Funds reported $555M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2022, up 8.7% quarter-over-quarter.
  • 27 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2022 and 12 closed out, a net change of +15 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2022 was State Street, an estimated $24.3M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2022 was NEA Management Company, an estimated $27.2M sold.

Based on aggregated 13F filings for Q3 2022.